摘要
目的对糖肽类抗菌药物无效的医院获得性耐甲氧西林金黄色葡萄球菌(MRSA)肺炎后续使用利奈唑胺治疗有效的病例进行分析,给临床使用提供意见。方法对该院1例急性硬膜下血肿清除术后医院获得性MRSA肺炎的患者进行抗菌药物分析,对糖肽类抗菌药物和利奈唑胺的疗效和经济学指标进行循证评价。结果该患者使用糖肽类抗菌药物治疗后疗效不佳,换为利奈唑胺抗感染治疗获得成功。该患者每日使用2g万古霉素,400mg仿制替考拉宁和1 200mg利奈唑胺,日均费用分别为497、341和788元。结论可以选择利奈唑胺治疗糖肽类抗菌药物无效的医院获得性MRSA肺炎。
Objective To analyze the case of inezolid in effectively treating hospital-acquired methicillin-resistant staphylococcus aureus（MRSA）pneumonia after ineffective glycopeptide antibiotics treatment in order to provide opinions for the clinical use.Methods The antibacterial drugs analysis was performed on 1 case of hospital-acquired MRSA pneumonia after acute subdural hematoma removal operation in this hospital,and the curative effects and economic indicators of glycopeptide antibacterial drugs and inezolid were conducted the evidence-based evaluation.Results Using glycopeptide antibacterial drugs in this patient had poor curative effect,and then changing to inezolid anti-infection treatment obtained the success.This patient used vancomycin 2 g,generic teicoplanin 400 mg and inezolid 1 200 mg per day;the average daily costs were 497,341,788 Yuan respectively.Conclusion Linezolid can be selected for treating hospital-acquired MRSA pneumonia patient after ineffective glycopeptide antibacterial drugs treatment.
出处
《重庆医学》
CAS
北大核心
2017年第33期4664-4666,共3页
Chongqing medicine
基金
重庆市卫生和计划生育委员会2015年医学科研计划项目(2015MSXM008)
关键词
耐甲氧西林金黄色葡萄球菌
医院获得性肺炎
利奈唑胺
糖肽类抗菌药
methicillin resistant staphylococcus aureus
hospital acquired pneumonia
linezolid
glucopeptide antibacterial drugs
